AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer

by Inveready Asset Management

The biopharmaceutical company Ability Pharmaceuticals SL announced today that it has been awarded €5 million blended financing from the Horizon Europe, European Innovation Council (EIC) Accelerator ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Mediterrania Capital Partners completes ...

by Mediterrania Capital Partners

Over the tenure of MC III’s investment, TGCC has not only achieved f...

Photos Stream